| Multiple Myeloma
Xgeva vs Mozobil
Side-by-side clinical, coverage, and cost comparison for multiple myeloma.Deep comparison between: Xgeva vs Mozobil with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsMozobil has a higher rate of injection site reactions vs Xgeva based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Mozobil but not Xgeva, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Xgeva
Mozobil
At A Glance
SC injection
Every 4 weeks
RANKL inhibitor
SC injection
Once daily for up to 4 days
CXCR4 antagonist
Indications
- Multiple Myeloma
- Metastatic malignant neoplasm to bone
- Giant Cell Tumor of Bone
- Humoral hypercalcemia of malignancy (disorder)
- Lymphoma, Non-Hodgkin
- Multiple Myeloma
Dosing
Multiple Myeloma, Metastatic malignant neoplasm to bone 120 mg SC every 4 weeks in the upper arm, upper thigh, or abdomen.
Giant Cell Tumor of Bone, Humoral hypercalcemia of malignancy (disorder) 120 mg SC every 4 weeks with additional 120 mg doses on Days 8 and 15 of the first month of therapy, in the upper arm, upper thigh, or abdomen.
Lymphoma, Non-Hodgkin, Multiple Myeloma 0.24 mg/kg SC (or 20 mg fixed dose for patients <=83 kg) once daily approximately 11 hours prior to apheresis for up to 4 consecutive days, following filgrastim 10 mcg/kg once daily for 4 days; maximum 40 mg/day.
Renal Impairment (CrCl <=50 mL/min) Reduce dose by one-third to 0.16 mg/kg SC (or 13 mg fixed dose for patients <=83 kg); maximum 27 mg/day.
Contraindications
- Pre-existing hypocalcemia
- Known clinically significant hypersensitivity to Xgeva or denosumab products
- History of hypersensitivity to plerixafor
Adverse Reactions
Most common (>=25%) Fatigue/asthenia, hypophosphatemia, nausea
Serious Dyspnea, osteonecrosis of the jaw, hypocalcemia, atypical subtrochanteric and diaphyseal femoral fracture, multiple vertebral fractures following treatment discontinuation
Postmarketing Severe symptomatic hypocalcemia (including fatal cases), severe symptomatic hypercalcemia following treatment discontinuation, hypersensitivity including anaphylactic reactions, severe musculoskeletal pain, lichenoid drug eruptions, alopecia
Most common (>=10%) Diarrhea, nausea, injection site reactions, fatigue, headache, arthralgia, dizziness, vomiting
Serious Anaphylactic shock, hypersensitivity reactions, tumor cell mobilization, hyperleukocytosis, decreased platelet counts, splenic enlargement
Postmarketing Splenomegaly, splenic rupture, anaphylactic reactions including anaphylactic shock, abnormal dreams and nightmares
Pharmacology
Xgeva is a RANKL inhibitor; it binds to RANKL, a protein essential for osteoclast formation, function, and survival, thereby preventing osteoclast-mediated bone resorption and modulating calcium release from bone in solid tumor bone metastases, multiple myeloma, giant cell tumor of bone, and hypercalcemia of malignancy.
Plerixafor is a CXCR4 chemokine receptor inhibitor that blocks binding of stromal cell-derived factor-1alpha (SDF-1alpha), disrupting HSC anchoring in the bone marrow and mobilizing hematopoietic stem cells to the peripheral blood for apheresis collection.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Xgeva
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (9/12) · Qty limit (11/12)
Mozobil
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Xgeva
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Mozobil
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Xgeva
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (2/3)
Mozobil
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Xgeva.
Cost estimate not availableCancerCare: Chemotherapy Induced Neutropenia
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
MozobilView full Mozobil profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.